

Switching treatments in psoriasis: a targeted literature review

Supplementary Material

Table S1: Search strategy.

Search terms	Number	Query	
Disease area	#1	Psoriasis[mh] OR moderate-to-severe psoriasis[tiab] OR moderate to severe psoriasis[tiab] OR moderate-severe psoriasis[tiab] OR plaque psoriasis[tiab]	
Treatments	#2	Switch* OR treatment switching[mh] OR "treatment switch" OR "switching therapy" OR "switching therapies"	
	#3	#1 AND #2	
All clinical trials	#4	Randomized Controlled Trial[pt] OR Controlled Clinical Trial[pt] OR Pragmatic Clinical Trial[pt] OR Clinical Study[pt] OR Adaptive Clinical Trial[pt] OR Equivalence Trial[pt]	
	#5	Clinical Trial[pt] OR Clinical Trial, Phase I[pt] OR Clinical Trial, Phase II[pt] OR Clinical Trial, Phase III[pt] OR Clinical Trial, Phase IV[pt] OR Clinical Trial Protocol[pt]	
	#6	Multicenter Study[pt]	
	#7	Clinical Studies as Topic[mh]	
	#8	Clinical Trial[mh] OR Clinical Trials as Topic[mh] OR Clinical Trial Protocol[mh] OR Clinical Trial Protocols as Topic[mh]	
	#9	Multicenter Study[mh] OR Multicenter Studies as Topic[mh]	
	#10	Random Allocation[mh]	
	#11	Double-Blind Method[mh]	
	#12	Single-Blind Method[mh]	
	#13	Placebos[mh]	
	#14	Control Groups[mh]	
	#15	Cross-Over Studies[mh]	
	#16	random*[tiab] OR sham[tiab] OR placebo*[tiab]	
	#17	(singl*[tiab] OR doubl*[tiab]) AND (blind*[tiab] OR dumm*[tiab] OR mask*[tiab])	
	#18	(tripl*[tiab] OR trebl*[tiab]) AND (blind*[tiab] OR dumm*[tiab] OR mask*[tiab])	
	#19	control*[tiab] AND (study[tiab] OR studies[tiab] OR trial*[tiab] OR group*[tiab])	
	#20	Clinical[tiab] AND (study[tiab] OR studies[tiab] OR trial*[tiab])	
	#21	Nonrandom*[tiab] OR non-random*[tiab] OR non-random*[tiab] OR quasi-random*[tiab] OR quasirandom*[tiab]	
	#22	Phase[tiab] AND (study[tiab] OR studies[tiab] OR trial*[tiab])	
	#23	(crossover[tiab] OR cross-over[tiab]) AND (study[tiab] OR studies[tiab] OR trial*[tiab])	
	#24	(multicent*[tiab] OR multi-cent*[tiab]) AND (study[tiab] OR studies[tiab] OR trial*[tiab])	
	#25	Allocated[tiab]	
	#26	("open label"[tiab] OR open-label[tiab]) AND (study[tiab] OR studies[tiab] OR trial*[tiab])	
	#27	(equivalence[tiab] OR superiority[tiab] OR non-inferiority[tiab] OR noninferiority[tiab]) AND (study[tiab] OR studies[tiab] OR trial*[tiab])	
	#28	"pragmatic study"[tiab] OR "pragmatic studies"[tiab]	
	#29	(pragmatic[tiab] OR practical[tiab]) AND (trial*[tiab])	
	#30	(quasiexperimental[tiab] OR quasi-experimental[tiab]) AND (study[tiab] OR studies[tiab] OR trial*[tiab])	
	#31	Trial[tiab]	
	#32	#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31	
	Irrelevant study types	#33	"real world"[tiab] OR real-world*[tiab] OR observational stud*[tiab] OR observational study[pt]
		#34	#32 NOT #33
	Excluding animal studies	#35	Animals[mh]
#36		Animal experimentation[mh]	
#37		Models, animal[mh]	
#38		Vertebrates[mh]	
#39		#35 OR #36 OR #37 OR #38	
#40		Humans[mh]	
#41		#39 NOT #40	

	#42	#34 NOT #41
	#43	#3 AND #42
Year filter	#44	#43 AND ("2014/04/26"[Date – Publication]: "2024/04/26"[Date – Publication])

Table S2: Time points of treatment switch and data cut-off.

Treatment switched from	Treatment switched to	Treatment switch time point(s) (Week)	Data cut-off (Week)	Reference
Secukinumab	Bimekizumab	48	96	Kokolakis 2023
Adalimumab	Bimekizumab	24	72	Kokolakis 2023
Ustekinumab	Bimekizumab	52	100	Kokolakis 2023
Adalimumab	Risankizumab	16	44	Reich 2019
Phosphodiesterase-4 inhibitor	Risankizumab	16	52	Stein Gold 2023
Adalimumab	Guselkumab	28	48	Reich 2017
Ustekinumab	Guselkumab	16	52	Langley 2018
Fumaric acid esters	Guselkumab	32	56	Thaçi 2024
Etanercept	Ixekizumab	12	60	Blauvelt 2017
Etanercept	Tildrakizumab	28	52	Kimball 2020
Etanercept	Certolizumab pegol	16	48	Warren 2021
Adalimumab	GP2017	17/23/29*	51	Blauvelt 2018
Ustekinumab	ATV04	16	52	Feldman 2023
Etanercept	GP2015	12/18/24*	30	Gerdes 2018
Etanercept	Phosphodiesterase-4 inhibitor	16	104	Reich 2018

*Multiple treatment switches performed between the reference product and biosimilar

As participants received initial treatments and switched treatments for different durations, it is difficult to compare efficacy scores between the studies. The most common time point of treatment switch was Week 16, which was reported in six of the 15 clinical trials. The other trials reported treatment switches ranging from Week 12 to Week 52, with studies on biosimilars reporting multiple treatment switches throughout. Data cut-off ranged between Week 30 and Week 104, with the most common data cut-off being Week 52, which was reported in four of the 15 clinical trials.